PTRN beats and raises — options flash a warning

The Street is broadly bullish but lately cautious on valuation. The most recent batch of analyst moves, from early March, saw JP Morgan's Doug Anmuth lower his target from $21 to $17 while keeping an Overweight. Stifel and Baird both trimmed targets modestly to $21 and $20 respectively, also maintaining positive ratings. The mean target across covering analysts runs to around $21 — roughly 50% above the current price of $14.01. That is a wide gap, and the stock's year-to-date gain of 21.4% has closed some of it, but the analyst data is now over two months old. Given the guidance raise, revisions upward are a plausible next step. The EPS surprise factor score ranks in the 86th percentile, and 30-day EPS momentum sits at the 83rd — pointing to a company that has been consistently surprising to the upside. The PE stands at 27x and EV/EBITDA at 11.2x, both creeping higher over the past 30 days as the price has recovered, though neither looks stretched in the context of the growth trajectory management just reaffirmed.

Ownership is tightly held and concentrated at the top. The Wright Irrevocable Trust holds 25.6% and the Alder Irrevocable Trust a further 16.6%. Knox Lane LP controls 15.9%. Together, those three positions account for more than half the company. The float is therefore narrow, which amplifies any movement in institutional flows among the smaller holders. Wasatch Advisors added 906,000 shares in Q1, Norges Bank Investment Management opened a new 2.25M-share position in H2 2025, and Vanguard added 450,000 shares. None of these are large in absolute terms, but the direction is consistent — institutional investors have been adding. On the insider side, the most recent activity of note is the CFO's small sale in February at $10.53, unremarkable given the stock has since rallied through $14. The more meaningful data point is director John Bailey's purchase of 302,000 shares across two days in late September 2025 at roughly $12.50-$13.40, an aggregate outlay of nearly $3.9M. The stock is now above those levels.

With the Q1 print now digested, the next confirmed event is a further earnings call dated May 15. The earnings history shows the last release in early March produced a one-day decline of 5.9%, before recovering 4% over the following week — a pattern of initial sell-the-news followed by buyers stepping in. What to watch from here is whether analyst targets get revised materially upward in response to the guidance raise, and whether the PCR spike proves to be a short-lived hedge or the opening of a more sustained defensive posture in an otherwise lightly shorted name.